(Q35198060)

7 August 2017

1 reference

title

The rotenone model of Parkinson's disease: genes, environment and mitochondria (English)

1 reference

7 August 2017

1 reference

1 reference

J Timothy Greenamyre

1

1 reference

7 August 2017

Ranjita Betarbet

series ordinal

2

1 reference

7 August 2017

Todd B Sherer

series ordinal

3

1 reference

7 August 2017

language of work or name

1 reference

1 August 2003

1 reference

Parkinsonism and Related Disorders

7 August 2017

published in

1 reference

7 August 2017

volume

9 Suppl 2

1 reference

7 August 2017

page(s)

S59-64

1 reference

Pathology and biology of the Lewy body

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Alpha-synuclein in Lewy bodies

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

MITOCHONDRIAL FUNCTION IN PARKINSON'S DISEASE

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Abnormalities of the electron transport chain in idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Mitochondrial complex I deficiency in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Failure of the ubiquitin-proteasome system in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

The ubiquitin pathway in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Induction of alpha-synuclein aggregation by intracellular nitrative insult.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Parkinson's disease: a case-control study of occupational and environmental risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Occupational categories at risk for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Pesticides and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

1 reference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

New inhibitors of complex I of the mitochondrial electron transport chain with activity as pesticides

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

alpha-synuclein gene haplotypes are associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Parkinson's disease, pesticides, and glutathione transferase polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Mitochondria in the etiology and pathogenesis of parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

The etiology of Parkinson's disease with emphasis on the MPTP story

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Pargyline Prevents MPTP-Induced Parkinsonism in Primates

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Electron transfer complex I defect in idiopathic dystonia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Origin and functional consequences of the complex I defect in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Inhibitors of NADH-ubiquinone reductase: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

In vivo labeling of mitochondrial complex I (NADH:ubiquinone oxidoreductase) in rat brain using [(3)H]dihydrorotenone.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

[3H]dihydrorotenone binding to NADH: ubiquinone reductase (complex I) of the electron transport chain: an autoradiographic study.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Interaction of alpha-phenyl-N-tert-butyl nitrone and alternative electron acceptors with complex I indicates a substrate reduction site upstream from the rotenone binding site.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2803%2900023-3

7 January 2021

10.1016/S1353-8020(03)00023-3

Identifiers

DOI

1 reference

7 August 2017

1 reference